Wegovy ® Semaglutide 0.5mg

160

WEGOVY® (semaglutide) injection 0.5 mg is an injectable prescription medicine that may help adults and children aged ≥12 years with obesity (BMI ≥30 for adults, BMI ≥ 95th percentile for age and sex for children), or some adults with excess weight (BMI ≥27) (overweight) who also have weight-related medical problems to help them lose weight and keep it off. Wegovy® should be used with a reduced calorie meal plan and increased physical activity

 

 

Quantity Discounts

QuantityPrice
5 +152

Quantity Discounts

QuantityPrice
10 +144

Quantity Discounts

QuantityPrice
15 +136

Quantity Discounts

QuantityPrice
20 +112

Description

WEGOVY® (semaglutide) injection 0.5 mg is an injectable prescription medicine that may help adults and children aged ≥12 years with obesity (BMI ≥30 for adults, BMI ≥ 95th percentile for age and sex for children), or some adults with excess weight (BMI ≥27) (overweight) who also have weight-related medical problems to help them lose weight and keep it off. Wegovy® should be used with a reduced calorie meal plan and increased physical activity

 

 

 

 

Wegovy® contains semaglutide and should not be used with other semaglutide-containing products or other GLP-1 receptor agonist medicines

 

It is not known if Wegovy® is safe and effective when taken with other prescription, over-the-counter, or herbal weight loss products

 

It is not known if Wegovy® can be used safely in people with a history of pancreatitis

 

It is not known if Wegovy® is safe and effective for use in children under 12 years of age.

 

 

 

 

 

 

 

Wegovy® is the first and only prescription weight-management medicine taken once weekly. It’s taken on the same day each week, any time of day, with or without food.

 

Wegovy® is available in 5 doses ranging from 0.25 mg to 2.4 mg, each of which is taken once a week. Each dose comes in a different color pen.

Reviews

There are no reviews yet.

Be the first to review “Wegovy ® Semaglutide 0.5mg”

Your email address will not be published. Required fields are marked *